Regenicin, Amarantus BioScience deal

Amarantus purchased IP related to Regenicin’s PermaDerm for $3.5 million in cash plus 37.5 million shares of Amarantus common stock valued at $3 million. The IP includes rights and claims under litigation with Lonza Group Ltd. (SIX:LONN, Basel, Switzerland). Additionally, Regenicin will receive $450,000 in attorney fees to cover Lonza litigation fees. ...